• Login:
  • Email Address:

    Password:


  • Register for Access

Welcome to Mitsubishi Tanabe Pharma America's 

Investigator Initiated Trials Portal

ANNOUNCEMENT

Due to migration to a new system, beginning Tuesday, Jan 3rd, 2023, Mitsubishi Tanabe Pharma America (MTPA) transitioned to a new software system called CyberGrants. Due to this transition, effective Friday, Dec 9th, 2022, MTPA decommissioned its existing software system, SteepRock. 

The new system CyberGrants is Live and MTPA is now submitting applications. Please submit all funding request applications for Charitable Contributions, Educational Grants, and Sponsorships via the following website:  https://www.mt-pharma-america.com/funding-requests/
Funding requests for any new Investigator Initiated Trials (IITs) are not being accepted at this time. Thank you for your understanding as we transition to a newer funding request management system. We value your patience and look forward to future partnerships.

Mitsubishi Tanabe Pharma America, Inc. (MTPA) is committed to supporting Investigator Initiated Trials that foster the advancement of scientific and clinical knowledge and improve patient care. Our Investigator Initiated Trials (IITs) Program has been created to provide support for Investigator-Initiated clinical research or Health Economics Outcome Independent Research that illustrates the potential to foster knowledge and understanding of MTPA’s product(s). Support from MTPA shall be provided as funding.
MTPA will receive and review applications for IITs conducted in the United States utilizing MTPA’s product(s) in the following areas:

  • Clinical research in patients involving the disease states or therapeutic areas for which MTPA’s product(s) are indicated
  • Health Economic Outcome Research proposals involving patients who have been prescribed MTPA’s product(s).
  • Maximum duration of study must be 2 years with progress reports from the applicant at the end of every 12 months.
  • Where financial support is requested, funding is only intended to cover legitimate research expenses with a maximum 25% overhead cost allowed in general, excluding equipment purchase. An amount in excess of 25% may be approved by MTPA, in its discretion upon a factual showing of necessity.
  • The study protocol must be IRB approved and adhere to Good Clinical Practices including all applicable laws, regulations, industry codes and guidelines.
  • Research Institution and PI must commit to MTPA’s pharmacovigilance and product complaint reporting requirements.
  • The PI is entirely responsible for the planning and execution of the study. Any publication of the study results is the responsibility of the PI and the authorship group he/she selects (per ICMJE and GPP3 requirements).

All applications will be reviewed for scientific merit, innovation, clinical impact on patients, and compliance with MTPA policy and requirements. Applications will be approved at MTPA’s sole discretion. At this time, any incomplete application or application in the following areas will not be considered for review:

  • Research that has already been commenced (e.g., IRB approved and on-going)
  • Clinical research already being planned or sponsored by MTPA or an affiliate
  • Continuing Medical Education (CME) or other educational activities
  • Event sponsorship
  • Research supported by patient or advocacy organizations Research that does not comply with all applicable laws, regulations, rules, and industry codes related to clinical and/or non-clinical research
  • Pre-clinical study
  • Unsolicited research (clinical study, HEOR activities) for people haven’t used/will not use approved MTPA products; or
  • Not otherwise eligible according to the criteria in above eligible areas.

MTPA’s IITs Applicants are required to comply with all applicable laws, regulations, rules, and industry codes related to clinical and/or non-clinical research.

To submit a request, please first create an account using the 'Register for Access' Link on the left.  If you already have an account, please enter your login details to the left. The link contains detailed information on the submission process, including the submission fields to complete to finalize your application. All required submission fields must be complete, and requested documents uploaded, in order for MTPA to consider your application for review.

Applications are reviewed on a quarterly basis.
Once an application is approved, the Investigator will be notified via email within six (6) weeks following the submission deadline.

NOTE: All Proposals must be submitted via the MTPA online IIT application portal. Hard copies will not be accepted.

Applications for IITs are not being accepted in 2022. We will update this web page once the new submission period is open.

The information and/or requirements of the IIT are subject to change at any time at MTPA’s sole discretion. MTPA has no obligation to approve applications received.

To contact the Mitsubishi Tanabe Pharma America team:
Email: IRP@MT-Pharma-US.com
For Technical Support, please contact SteepRock Client Services:
Email: Support@SteepRockInc.com
Phone: +1 718-576-1406 (M-F 8am - 6pm US ET)


The information and/or requirements of the IRP are subject to change at any time at MTPA’s sole discretion. MTPA has no obligation to approve applications received.


To contact the Mitsubishi Tanabe Pharma America team:
Email: IRP@MT-Pharma-US.com
For Technical Support, please contact SteepRock Client Services:
Email: Support@SteepRockInc.com
Phone: +1 718-576-1406 (M-F 8am - 6pm US ET)